Davita Inc vs Starbucks Corp — how do they compare? Davita Inc trades at $178.01 (market cap $11.29B), while Starbucks Corp trades at $92.57 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 9.4× Davita Inc's market cap, and Starbucks Corp pays a 2.7% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Starbucks Corp for 190 Days on average.
| DVA | SBUX | |
|---|---|---|
Market Cap | $11.29B | $106.26B |
Volume | 582,204 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $108.55 |
52-Week Low | $103.87 | $78.46 |
Typical Hold Time | 113 Days | 190 Days |
Enterprise Value | $24.01B | $125.08B |
Dividend Yield | — | 2.7% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Starbucks (SBUX) trades at $93.58, down 2.63% on the day, as the company navigates a strategic restructuring with 250 North American store closures. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Fundamentally, SBUX maintains stable revenue growth but faces margin compression, with net income declining to $1.86B in 2025. Analyst consensus remains positive with a $115.50 price target, though recent news highlights operational challenges and geopolitical tensions.
The outlook for SBUX balances near-term headwinds from restructuring costs against long-term growth potential in international markets. Investment opportunities include strong brand equity and dividend consistency, while risks involve labor relations, Chinese market exposure, and execution of the store optimization strategy. The current valuation at 53.88x P/E requires sustained earnings recovery to justify upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →